Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
92.2M
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
3.56M
-
Shares change
-
+980K
-
Total reported value, excl. options
-
$4.02M
-
Value change
-
+$1.1M
-
Number of buys
-
9
-
Number of sells
-
-2
-
Price
-
$1.13
Significant Holders of Context Therapeutics Inc. - Common Stock, par value $0.001 per share (CNTX) as of Q4 2023
25 filings reported holding CNTX - Context Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q4 2023.
Context Therapeutics Inc. - Common Stock, par value $0.001 per share (CNTX) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.56M shares
of 92.2M outstanding shares and own 3.86% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (975K shares), Ally Bridge Group (NY) LLC (726K shares), VANGUARD GROUP INC (596K shares), Affinity Asset Advisors, LLC (329K shares), UBS OCONNOR LLC (297K shares), HighTower Advisors, LLC (126K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (106K shares), Mill Creek Capital Advisors, LLC (105K shares), GEODE CAPITAL MANAGEMENT, LLC (97.2K shares), and NORTHERN TRUST CORP (37.2K shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.